These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 24501158

  • 21. Identification of a novel series of 3-piperidinyl-5-sulfonylindazoles as potent 5-HT6 ligands.
    Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ.
    Bioorg Med Chem Lett; 2009 Jun 15; 19(12):3214-6. PubMed ID: 19433358
    [Abstract] [Full Text] [Related]

  • 22. Computational approaches to the design of novel 5-HT6 R ligands.
    Ivanenkov YA, Majouga AG, Veselov MS, Chufarova NV, Baranovsky SS, Filkov GI.
    Rev Neurosci; 2014 Jun 15; 25(3):451-67. PubMed ID: 24867282
    [Abstract] [Full Text] [Related]

  • 23. Influence of social isolation in the rat on serotonergic function and memory--relevance to models of schizophrenia and the role of 5-HT₆ receptors.
    Marsden CA, King MV, Fone KC.
    Neuropharmacology; 2011 Sep 15; 61(3):400-7. PubMed ID: 21414329
    [Abstract] [Full Text] [Related]

  • 24. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders.
    Nirogi R, Jayarajan P, Shinde A, Mohammed AR, Grandhi VR, Benade V, Goyal VK, Abraham R, Jasti V, Cummings J.
    Biomolecules; 2023 Feb 07; 13(2):. PubMed ID: 36830678
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases.
    Sudoł S, Cios A, Jastrzębska-Więsek M, Honkisz-Orzechowska E, Mordyl B, Wilczyńska-Zawal N, Satała G, Kucwaj-Brysz K, Partyka A, Latacz G, Olejarz-Maciej A, Wesołowska A, Handzlik J.
    Int J Mol Sci; 2021 Oct 05; 22(19):. PubMed ID: 34639113
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease.
    Upton N, Chuang TT, Hunter AJ, Virley DJ.
    Neurotherapeutics; 2008 Jul 05; 5(3):458-69. PubMed ID: 18625457
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Multitargeting the Action of 5-HT6 Serotonin Receptor Ligands by Additional Modulation of Kinases in the Search for a New Therapy for Alzheimer's Disease: Can It Work from a Molecular Point of View?
    Czarnota-Łydka K, Kucwaj-Brysz K, Pyka P, Haberek W, Podlewska S, Handzlik J.
    Int J Mol Sci; 2022 Aug 07; 23(15):. PubMed ID: 35955902
    [Abstract] [Full Text] [Related]

  • 32. Identification of a series of benzoxazoles as potent 5-HT6 ligands.
    Liu KG, Lo JR, Comery TA, Zhang GM, Zhang JY, Kowal DM, Smith DL, Di L, Kerns EH, Schechter LE, Robichaud AJ.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1115-7. PubMed ID: 19152787
    [Abstract] [Full Text] [Related]

  • 33. A new serotonin 5-HT6 receptor antagonist with procognitive activity - Importance of a halogen bond interaction to stabilize the binding.
    González-Vera JA, Medina RA, Martín-Fontecha M, Gonzalez A, de la Fuente T, Vázquez-Villa H, García-Cárceles J, Botta J, McCormick PJ, Benhamú B, Pardo L, López-Rodríguez ML.
    Sci Rep; 2017 Jan 24; 7():41293. PubMed ID: 28117458
    [Abstract] [Full Text] [Related]

  • 34. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
    Floresco SB, Geyer MA, Gold LH, Grace AA.
    Schizophr Bull; 2005 Oct 24; 31(4):888-94. PubMed ID: 16079387
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets.
    Terry AV, Buccafusco JJ, Wilson C.
    Behav Brain Res; 2008 Dec 16; 195(1):30-8. PubMed ID: 18241938
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.